Eli Lilly and Company · Q3 2025
ReportedOct 30, 2025
Period endedSep 30, 2025
Rule of 40+92
The quarter in short
Revenue $17.60B, up 53.9% year over year and 13.1% on the quarter. EPS $6.21, up 480.4% year over year and down 1.3% on the quarter. Free cash flow $6.75B, up 185.8% year over year and 385.5% on the quarter. Rule of 40 score +92.
Reported this quarter
Revenue
$17.60B
QoQ +13.1%
YoY +53.9%
EPS
$6.21
QoQ −1.3%
YoY +480.4%
Free Cash Flow
$6.75B
QoQ +385.5%
YoY +185.8%
Gross Margin
82.9%
QoQ −1.4 pp
YoY +1.9 pp
FCF Margin
38.3%
QoQ +29.4 pp
YoY +17.7 pp
P/E Ratio
37.2
QoQ −26.6%
YoY −61.0%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 59478.
HTML
8-K results announcement
Filed Oct 30, 2025
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
213 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Sep 30, 2025, filed Oct 30, 2025
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure LLY has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q3 2025, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings